Form 4: Teladoc Health CAO Sells Shares for Tax Obligations

Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, sold 2,972 shares of common stock to cover tax withholdings following the vesting of restricted stock units.

Summary

• Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported changes in beneficial ownership.
• On October 1, 2025, 8,333 restricted stock units (RSUs) vested and converted into an equal number of common shares. These RSUs were part of a 25,000 unit grant made on October 1, 2024, with one-third vesting on the first anniversary.
• On October 2, 2025, Mr. Catapano sold 2,972 shares of Teladoc Health common stock at a price of $7.885 per share.
• This sale was conducted to satisfy tax withholding obligations related to the vesting of the restricted stock unit awards.
• Following these transactions, Mr. Catapano directly beneficially owns 5,361 shares of common stock and 16,667 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, which is a neutral event for the company's operational performance.

Positives

• The vesting of 8,333 restricted stock units indicates the fulfillment of long-term incentive compensation for the Chief Accounting Officer.
• The continued holding of 16,667 restricted stock units by the Chief Accounting Officer demonstrates ongoing alignment of management's interests with shareholder value.

Negatives

• The sale of 2,972 common shares, even for tax purposes, results in a reduction of the Chief Accounting Officer's direct equity ownership in the company.

Future Outlook

The remaining 16,667 restricted stock units held by the Chief Accounting Officer are scheduled to vest in eight substantially equal quarterly installments after the initial vesting date.

Industry Context

This transaction is a routine insider filing, common across publicly traded companies, where executives receive equity compensation in the form of restricted stock units. The subsequent sale of shares to cover tax obligations upon vesting is a standard practice in such compensation structures.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale of shares for tax withholding is a standard and widely accepted practice for executive equity compensation across various industries, including healthcare technology.
• This type of transaction does not typically indicate a change in company fundamentals or management's outlook, aligning with similar routine insider filings observed in companies like Amwell (AMWL) or Livongo (acquired by Teladoc), where executives manage their equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, expected insider transaction for tax purposes. It confirms the Chief Accounting Officer's continued equity stake and alignment with company performance.
• Management: The Chief Accounting Officer's compensation structure includes equity, aligning their interests with long-term company performance.

Next Steps

• The remaining 16,667 restricted stock units will vest in eight substantially equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Accounting Officer sold shares to cover tax obligations arising from RSU vesting. Such transactions are common and do not typically reflect a change in management's outlook or the company's fundamentals. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Restricted Stock Units, Stock Sale, Tax Withholding, Joseph Ronald Catapano, Chief Accounting Officer